Advaxis Stock Price

0.0034 (0.93%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Advaxis Inc ADXS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0034 0.93% 0.37 19:51:08
Close Price Low Price High Price Open Price Previous Close
0.3882 0.34 0.399 0.3517 0.3666
Bid Price Ask Price Spread News
0.3723 0.3896 0.0173 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,900 2,615,877 $ 0.3645919 $ 953,728 1,312,035 0.202 - 1.57
Last Trade Time Type Quantity Stock Price Currency
19:48:41 formt 886 $ 0.37 USD

Advaxis Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 24.50M 66.23M 66.16M $ 20.88M $ - 0.02 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Advaxis News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ADXS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.4310.4830.340.3768822,520,857-0.061-14.15%
1 Month0.4840.550.340.42355681,441,182-0.114-23.55%
3 Months0.5460.660.340.49564851,087,437-0.176-32.23%
6 Months0.55640.880.340.59750681,215,344-0.1864-33.5%
1 Year0.21561.570.2020.67837734,278,8840.154471.61%
3 Years4.6010.800.1810.93534672,144,006-4.23-91.96%
5 Years15.1316.2950.1812.591,612,532-14.76-97.55%

Advaxis Description

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.